

# Bone mineral density and osteoporosis related risk factors in type 2 diabetes mellitus

*by* Heri Nugroho

---

**Submission date:** 06-Jun-2024 08:17AM (UTC+0700)

**Submission ID:** 2396520365

**File name:** ineral\_density\_and\_osteoporosis\_related\_risk\_factors\_in\_t2dm.pdf (282.1K)

**Word count:** 4568

**Character count:** 25138

## Bone mineral density and osteoporosis related risk factors in type 2 diabetes mellitus

Heri Nugroho<sup>1</sup>, Rizki Kurniawan<sup>2</sup>, Cahya Tri Purnami<sup>3</sup>

<sup>1</sup>Division of Diabetes, Endocrine, and Metabolism, Department of Internal Medicine, Dr. Kariadi Hospital, Semarang, Indonesia

<sup>2</sup>Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Semarang, Indonesia

<sup>3</sup>Department of Biostatistics, Public Health Faculty, Diponegoro University, Semarang, Indonesia

### Article Info

#### Article history:

Received Jun 12, 2023

Revised Aug 22, 2023

Accepted Sep 1, 2023

#### Keywords:

Bone mineral density  
Diabetes mellitus  
Metabolic disorders  
Osteopenia  
Osteoporosis  
Risk factors

### ABSTRACT

Diabetes mellitus negatively affects bone tissue and unfavourably impacts bone mineral density (BMD), therefore increasing the probability of fractures through pathological mechanisms. This study aimed to explore the factors associated with BMD and osteoporosis risk in individuals with a diagnosis of type 2 diabetes mellitus (T2DM). An investigation was undertaken involving 49 patients diagnosed with T2DM who fulfilled the specified criteria. These individuals underwent BMD assessment as part of a cross-sectional study. The analysis encompassed both univariate and bivariate approaches, utilizing the Chi-square test ( $X^2$ ) and binary logistic regression methods. A total of 30 participants (61%) have decreased BMD. Among the participants aged 60 years and above, 83.4% exhibited a decreased BMD status (osteopenia and osteoporosis), in contrast to the under 60 years age group, in which 40% displayed decreased BMD status. Older age (>60 years) is a risk factor for decreasing bone density onset of diabetes mellitus (DM) diagnosis, duration of DM, glycemic control, body mass index (BMI), use of thiazolidinediones (TZD) drugs, kidney function, were not associated with lower BMD in T2DM patients.

This is an open access article under the CC BY-SA license.



### Corresponding Author:

Heri Nugroho

Division of Diabetes, Endocrine, and Metabolism, Department of Internal Medicine, Dr. Kariadi Hospital  
Prof Mr. Sunario Street, Tembalang, Semarang 50275, Indonesia

Email: khris\_heri@yahoo.com

## 1. INTRODUCTION

Type 2 diabetes mellitus (T2DM) exerts deleterious effects on bone tissue, thereby predisposing individuals to an increased risk of skeletal fractures, both vertebral and non-vertebral [1], [2]. The underlying mechanisms responsible for the impact of T2DM on bone health are intricate due to the frequent coexistence of obesity, which itself can have detrimental consequences on bone physiology. In addition, bone mineral density (BMD) increased variably in T2DM, an effect expected to increase bone strength [3], [4].

Osteoporosis is defined as the decrease in bone mass and damage to the microarchitecture of bone tissue that results in reduced bone density and strength and an increased risk of fracture [5], [6]. Large population-based studies of osteoporosis patients show that T2DM patients constitute 18% of the osteoporosis population [7]. Diabetes can contribute to skeletal disorders through various factors. These mechanisms involve changes in insulin and insulin-like growth factor (IGF) levels, hypercalciuria due to glycosuria, impaired kidney function, obesity, elevated levels of advanced glycation end products (AGEs) in collagen, vascular issues, nerve damage, and inflammation [8], [9].

Patients with both osteoporosis and diabetes mellitus (DM) exhibit a 16% higher prevalence of fractures compared to those with osteoporosis alone, even after adjusting for age and gender [7]. Among

women with type 2 DM, there is an elevated risk of hip and non-vertebra<sup>69</sup> fractures [10]-[13]. Prolonged diabetes duration and inadequate glycemic control are associated with increased risk of fracture and decreased BMD [3], [14]. While a higher body mass index (BMI) is generally linked to greater bone density, the protective effect diminishes once BMI exceeds 25 kg/m<sup>2</sup>, leading to a higher likelihood of fractures in specific areas [15].

Elevated blood glucose levels in DM disrupt fat metabolism, reduce insulin sensitivity, and promote inflammation, thereby exacerbating osteoporosis [16]. The use of thiazolidinediones (TZDs) has been linked with an augmented osteoporosis and fractures [17]. Diabetic nephropathy, affecting up to 50% of DM patients, impairs bone metabolism due to insufficient vitamin D<sup>30</sup> synthesis and reduced calcium absorption. Knowing the relationship between T2DM and osteoporosis, we aim to evaluate the profile of BMD and osteoporosis related risk factors that is present in individuals with T2DM. By examining these factors, the research aims to enhance understanding of osteoporosis in the T2DM population [14].

## 2. METHOD

A study with cross-sectional design was conducted in a Central General Hospital in Semarang, Central Java. The participants of this study were T1DM or T2DM patients who underwent BMD examination. Sampling was carried out using purposive sampling technique, obtaining a minimum sample size of 49 patients, referring to the results of the initial study obtained from the medical record installation and information system of the hospital reported that 49 patients with the main diagnosis of T2DM who had a BMD examination in the 2016-2021 period.

Inclusion criteria are patients previously diagnosed T2DM with complete clinical data who signed the informed consent. Exclusion criteria are patients with other types of DM, patients suffering from other diseases affecting bone metabolism, such as Cushing's syndrome, anorexia nervosa, premature menopause (age <40 years), hyperprolactinemia, panhypopituitarism, thyroid disease, parathyroid disease, gastrointestinal disease with impaired absorption of food, malignancy, hemophilia, thalassemia, epilepsy, multiple sclerosis, parkinsonism, rheumatoid arthritis, systemic lupus erythematosus, HIV/AIDS, amyloidosis, chronic obstructive pulmonary disease, tuberculosis, depression, and transplant recipients. Patients who perennially take drugs affecting bone metabolism, such as aluminum (in antacids), anticoagulants (heparin), anticonvulsants, aromatase inhibitors, barbiturates, cancer chemotherapy drugs, glucocorticoids ( $\geq 5$  mg/day prednisone or equivalent for three months<sup>57</sup>), gonadotropin-releasing hormone (GnRH) agonists, lithium, cyclosporine, tacrolimus, methotrexate, selective serotonin reuptake inhibitors, Tamoxifen® (premenopausal use), thyroid hormone, and warfarin<sup>36</sup>.

Minimum sample size was calculated with 5% type I error and 10% type II error and data from previous literature. A minimum sample size of 14 was obtained for each group [18], [19]. The research procedure has been approved on 14<sup>th</sup> October 2021 by the Health Research Ethics Commission (No.927/EC/KEPK-RSDK/2021). Patients and/or their guardians provided signed informed consent documents.

The measurement of body mass index was conducted using either the Body Composition Analyzer or manual methods. The classification<sup>31</sup> obesity was adjusted based on the WHO guidelines for the Asia-Pacific region, with categories including obese ( $\geq 25$ ), overweight (23-24.9), normal (18.5-22.9), and underweight ( $< 18.5$ ). For bone density assessment, a dual X-ray absorptiometry<sup>19</sup> (DXA) device was utilized. If the individual was aged 50 years or older, the T-Score was categorized as normal ( $\geq -1.0$ ), osteopenia ( $< -1.0$ ,  $> -2.5$ ), osteoporosis ( $\leq -2.5$ ), and severe osteoporosis ( $\leq -2.5$  with fracture). If the individual was younger than 50 years, the Z-score was categorized as normal ( $\geq -2.37$ ) or below the normal limits based on gender and age ( $< -2.0$ ).

The data underwent processing using Statistical Product and Service Solutions (SPSS) software version 19.0. Univariate analysis of categorical (nominal) data is presented in a frequency distribution, while numerical data is presented as minimum, maximum, mean  $\pm$  standard deviation (SD). Bivariate analysis was carried out in 2 stages, descriptive bivariate using cross table/row and column analysis and analytical bivariate using Chi-square test ( $X^2$ ). The significance of statistical test results using p-value  $< \alpha$  (0.05) was considered statistically significant. Further binary logistics regression will be performed for all known risk factors.

## 3. RESULTS AND DISCUSSION

This study was conducted during the period of January-February 2022, employing a sample of patients diagnosed with T2DM who underwent bone BMD examination. A total of 49 samples were selected and included in the final analysis. A total of 30 participants (61%) have decreased BMD. The average age of the subjects was determined to be<sup>62</sup> 59.4 years, and 34.7% of the participants were male. A noteworthy observation from the data is that more than half of the participants<sup>32</sup> (1%) were classified as obese. Detailed information regarding the participants' characteristics can be found in Table 1.

Table 1. Characteristics of study participants

Characteristics	n (%)	Mean ± SD
Age (years)		59.43 ± 8.77
Gender (Male)	17 (34.7%)	
History of smoking	9 (18.4%)	
History of fracture	8 (16.3%)	
Menopause	26 (53.1%)	
Use of pioglitazone	3 (6.1%)	
BMI		
Underweight	0 (0%)	
Normal	14 (28.6%)	
Overweight	8 (16.3%)	
Obese	27 (55.1%)	
Onset of DM Dx (years old)		49.80 ± 9.02
Duration of DM (years)		9.63 ± 7.75
HbA1c (%)		9.078 ± 1.99
eGFR (ml/min/1.73m <sup>2</sup> )		61.83 ± 26.79

eGFR: estimated Glomerular Filtration Rate

The age distribution displayed a relatively even distribution of  $\geq 60$  years. Among the 24 participants aged of  $\geq 60$  years (16.7%) are exhibited a normal BMD status. In contrast, 25 participants the  $< 60$  years (60%) displayed normal BMD status. A comprehensive overview of the BMD status categorized by age can be found in Table 2.

Table 2. BMD status of patients according the age

BMD status	Age	
	$\geq 60$ Years	$< 60$ Years
Normal	4 (16.7%)	15 (60%)
Osteopenia	16 (66.7%)	5 (20%)
Osteoporosis	3 (12.5%)	4 (16%)
Severe osteoporosis	1 (4.2%)	1 (4%)

After analyzing between characteristics of study participants and decreased BMD, we found that age  $\geq 60$  years old is associated with decreased BMD. Other variables have no significant association with decreased BMD as shown in Table 3. Multiple binary logistic regression was performed with the result of only age is significant as a risk factor for decreasing bone density as shown in Table 4.

Table 3. Association between known risk factors and decreased bone density

Characteristic		Normal BMD (n=19)		Decreased bone density (n=30)		p-value
		n	%	n	%	
Age (years)	$\geq 60$	4	21.1	20	66.7	0.002
	$< 60$	15	78.9	10	33.3	
Gender	Male	7	58	10	33	0.801
	Female	12	42	20	67	
Duration of DM (years)	$< 10$	7	37	17	57	0.176
	$\geq 10$	12	63	13	43	
BMI	Normal	7	58.3	5	41.7	0.110
	Obese & Overweight	12	32.4	25	67.6	
History of smoking	Yes	4	21	5	17	0.699
	No	15	79	25	83	
History of fracture	Yes	2	0.11	6	20	0.382
	No	17	0.89	24	80	
Use of pioglitazone	Yes	0	0	3	10	0.155
	No	19	100	27	90	
HbA1c (%)	$< 7$	3	33.3	6	66.7	0.711
	$\geq 7$	16	40.0	24	60.0	
eGFR (ml/min/1.73m <sup>2</sup> )	$\geq 60$	13	68	14	47	0.136
	$< 60$	6	32	16	53	

Table 4. Multiple binary logistics regression between known risk factors and decreased bone density

Characteristics	n	Odds ratio	95% Confidence interval	p-value
Age (years)				
≥60	4	14.64	2.12-100.7	0.006
<60	15	reference		
Gender				
Male	7	0.21	0.26-1.68	0.142
Female	12	reference		
Duration of DM (years)				
<10	7	0.53	0.09-2.98	0.473
≥10	12	reference		
BMI				
Normal	7	0.37	0.06-2.23	0.281
Obese and overweight	12	reference		
History of smoking				
No	15	1.13	0.13-9.57	0.908
Yes	5	reference		
History of fracture				
No	17	0.14	0.01-1.58	0.112
Yes	2	reference		
Use of pioglitazone				
No	19	0	0	0.999
Yes	0	reference		
HbA1c (%)				
<7	3	3.51	0.42-29.2	0.245
≥7	16	reference		
eGFR (ml/min/1.73m <sup>2</sup> )				
≥60	13	6.61	0.95-38.75	0.057
<60	6	reference		

Among individuals with osteoporosis, those who also have DM exhibited a higher incidence of comorbidities, resulting in a 16% increased prevalence of fractures when compared to osteoporosis patients without DM. This adjustment considered differences in age and gender distribution [7]. Several studies have shown that women with T2DM are at higher risk of fractures in the hip and non-vertebral bones to nondiabetic women [10]–[12]. An increased risk of hip fracture has been demonstrated by the odds ratio (OR) ranging from 1.2 to 1.7. While findings may differ, there seems to be a connection between extended duration of diabetes and inadequate glycemic control, leading to an elevated likelihood of fractures. Additionally, these factors are linked to a reduction in BMD [3], [14].

Our study observed a higher prevalence of decreased bone density in females compared to males, aligning with existing literature suggesting that postmenopausal estrogen deficiency in women makes them more susceptible to decreased bone density (type I involutonal osteoporosis) [20]. This is supported by the Study of Women's Health Across the Nation (SWAN) study which examined changes in BMD of the total lumbar and femoral neck in a community-based cohort with 292 premenopausal women and 141 in early postmenopausal women [21]. BMD remains stable in pre and early perimenopause [22], [23]. However, during late perimenopause and early postmenopausal period, there is a significant acceleration of bone loss with annual rates ranging from 1.0-2.3%. Regardless of race/ethnicity, women with lower body weight experience 35-55% higher bone loss rates compared to those with higher body weight [24].

Studies have shown that there was a direct correlation observed between an increasing BMI and the incidence of T2DM, while also exhibiting an association with increased bone mineral density at weight-bearing sites [15]. However, this association was not seen in our study. Heavier body weight provides some protection against bone loss, but this correlation is not linear. Once BMI exceeds 25 kg/m<sup>2</sup>, weight gain does not provide additional bone protection, and obese individuals have a higher likelihood of fractures in specific locations [25]. Given the association between T2DM and obesity, separating their contributions can be challenging [3].

We did not discover any association between decreasing BMD and onset of diabetes or duration of diabetes. This contrasted with a study by Zhao *et al.* in a population of diabetic nephropathy, which concluded that the duration of DM in the osteoporosis group was significantly higher ( $p < 0.05$ ) [14]. The different result may be attributed to small sample size, population differences and underestimation of DM duration particularly if the patient is diagnosed only after developing complications.

Inadequate glycemic control and longer diabetes duration can result in an increased risk of fracture [15]. However, we did not discover any correlation between glycemic control in type 2 diabetes mellitus (T2DM) and bone mineral density (BMD). This outcome aligns with a study conducted in the UK, which revealed that although inadequate glycemic control is linked to a heightened risk of low-trauma fractures in individuals with type 1 diabetes mellitus, this impact is not evident in those with type 2 diabetes mellitus [26]. Action to Control Cardiovascular Risk in Diabetes (ACCORD) study found that intensive glycemic control was not significantly associated with fracture or risk of falls compared with standard therapy [27]. Participants with an HbA1c of 8% had a 63% higher risk of hospitalization for fracture compared to those with an HbA1c of below 8%. Patients with unknown diabetes and pre-diabetes before starting the study had no increased risk of hospitalization compared with those with an HbA1c below 5.7% [5]. A meta-analysis of observational studies reported the HbA1c levels of >8% and hypoglycemia increases the risk of fracture in diabetic patients [28]. The risk of falls is influenced by various factors related to vision and balance. Factors



associated with vision encompass diabetic retinopathy, cataracts, retinopathy laser therapy, and episodes of hypoglycemia. Risks related to balance encompass peripheral neuropathy, foot ulcers, excessive urination, nighttime urination, and diminished reflexes. The heightened risk of hip fracture is linked to an increased likelihood of falls rather than a decrease in BMD [29].

In a cohort study comprising over 9,000 T2DM patients, the utilization of TZDs was linked to a 35% higher likelihood of experiencing hip fractures [17]. Furthermore, TZDs not only raised the risk of fractures but also led to a decrease in bone formation and an increase in bone resorption, ultimately resulting in a reduction in bone mass [28], [30], [31]. Double-blind, placebo-controlled randomized trials have shown that treatment with pioglitazone slightly increased risk of fracture compared to placebo. Population-based studies and meta-analyses have also reported an increased risk with women being more susceptible to the detrimental effects on bone than men [32]. The lack of a statistically significant association between the use of pioglitazone and osteoporosis incidence in this study may be attributed to the small number of samples (three patients).

Diabetic nephropathy affects up to 50% of diabetes patients and is a major cause of end stage kidney disease (ESKD). Insufficient vitamin D synthesis in diabetic nephropathy leads to insulin resistance, increased microalbumin secretion, and decreased renal hydroxylase activity. A reduction in 1.25-(OH)2D3 content reduces calcium absorption and bone formation, therefore the severity of diabetic nephropathy affects bone metabolism [14]. This is demonstrated in a Chinese study in 18 population of diabetic nephropathy patients, which concluded that the eGFR value in the osteoporosis group was significantly higher than the group without osteoporosis ( $p < 0.05$ ) [14]. However, we did not demonstrate any association between decreasing kidney function and decreasing BMD.

Caution is advised when interpreting the results of this study owing to several constraints. The primary limitation is the relatively small sample size, and a significant concern arises from the incomplete matching between subjects within each group. To enhance comprehension of the risk factors and the connection between type 2 diabetes and osteoporosis, it is advisable to undertake a more extensive case-control study with a balanced distribution of BMD outcomes. Such an investigation is anticipated to yield a more elucidating perspective on this subject.

#### 4. CONCLUSION

Our study found that 61% of the T2DM sample population have decreased BMD. Older (>60 years) T2DM individuals have a higher proportion of decreasing BMD (83.4%) compare to the younger (<60 years) counterpart (40%). Older age (>60 years) is a risk factor for decreasing bone density. Onset of DM diagnosis, duration of DM, glycemic control, BMI, use of TZD drugs, kidney function was not associated with lower BMD in T2DM patients.

This study emphasizes the significance of acknowledging the heightened susceptibility of people with T2DM to bone health concerns related to osteoporosis, particularly in older individuals. The results underscore the necessity for targeted interventions and preventive strategies, especially among the elderly, to mitigate the increased likelihood of bone fractures in this demographic. Although the research offers valuable insights, its constraints underscore the requirement for broader and more extensive inquiries to gain a deeper understanding of the complex association between T2DM and bone health.

#### ACKNOWLEDGEMENTS





The authors would like to extend appreciation to the patients, the nurses, and support staffs at Endocrinology Clinic of Dr. Kariadi Hospital for their valuable contributions in this study. The research was partially supported by Department of Internal Medicine Diponegoro University. The content of the study is entirely the responsibility of the authors and does not officially reflect the views of Department of Internal Medicine Diponegoro University. The authors acknowledge Kevin Gracia Pratama, who provided support in editing, formatting, and translating the manuscript.

#### REFERENCES





- [1] F. Koromani et al., "Vertebral fractures in individuals with type 2 diabetes: more than skeletal complications alone," *Diabetes Care*, vol. 43, no. 1, pp. 137–144, Jan. 2020, doi: 10.2337/DC190925.
- [2] T. Vilaca et al., "The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update," *Bone*, vol. 137, p. 115457, Aug. 2020, doi: 10.1016/j.bone.2020.115457.
- [3] B. Cortet, S. Lucas, I. Legroux-Gerot, G. Penel, C. Chauveau, and J. Paccou, "Bone disorders associated with diabetes mellitus and its treatments," *Joint Bone Spine*, vol. 86, no. 3, pp. 315–320, May 2019, doi: 10.1016/j.jbspin.2018.08.002.

- [4] S. A. Paschou, A. D. Dede, P. G. Anagnostou, Vryonidou, D. Morganstein, and D. G. Goulis, "Type 2 diabetes and osteoporosis: a guide to optimal management," *Journal of Clinical Endocrinology and Metabolism*, vol. 102, no. 10, pp. 3621–3634, Oct. 2017, doi: 10.1210/clinem.2017-00042.
- [5] Chandran *et al.*, "Development of the asia pacific consortium on osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region," *Osteoporosis International*, vol. 32, no. 7, p. 1249, Jul. 2021, doi: 10.1007/s00198-020-05742-0.
- [6] S. C. Thambiah and S. S. Yeap, "Osteoporosis in South-East Asian countries," *Clinical Biochemist Reviews*, vol. 41, no. 1, p. 29, 2020, doi: 10.3177/AACB-19-00034.
- [7] I. Goldshtein *et al.*, "Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients," *Archives of Osteoporosis*, vol. 13, no. 1, Dec. 2018, doi: 10.1007/S11657-018-0432-X.
- [8] K. Hygum, J. Starup-Linde, and B. L. Langdahl, "Diabetes and bone," *Osteoporosis and Sarcopenia*, vol. 5, no. 2, pp. 29–37, Jun. 2019, doi: 10.1016/J.AFOS.2019.05.001.
- [9] M. S. LeBoff *et al.*, "The clinician's guide to prevention and treatment of osteoporosis," *Osteoporosis International*, vol. 33, no. 10, p. 2049, Oct. 2022, doi: 10.1007/S00198-021-05900-Y.
- [10] T. Vilaca *et al.*, "The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update," *Bone*, vol. 137, p. 115457, Aug. 2020, doi: 10.1016/J.BONE.2020.115457.
- [11] Y. Guo, Y. Wang, F. Chen, J. Wang, and D. Wang, "Assessment of risk factors for fractures in patients with type 2 diabetes over 60 years old: a cross-sectional study from Northeast China," *Journal of Diabetes Research*, vol. 2020, 2020, doi: 10.1155/2020/1508214.
- [12] E. P. Thong *et al.*, "The diabetes-fracture association in women with type 1 and type 2 diabetes is partially mediated by falls: a 15-year longitudinal study," *Osteoporosis International*, vol. 32, no. 6, pp. 1175–1184, Jun. 2021, doi: 10.1007/S00198-020-05771-9.
- [13] P. Chotiyanwong *et al.*, "Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the international osteoporosis foundation epidemiology/quality of life working group," *Archives of Osteoporosis*, vol. 17, no. 1, p. 6, Dec. 2022, doi: 10.1007/S11657-022-01117-6.
- [14] Z. Zhao, "Correlation analysis of urine proteins and inflammatory cytokines with osteoporosis in patients with diabetic nephropathy," *Journal of Musculoskeletal Neuronal Interactions*, vol. 18, no. 3, p. 348, Sep. 2018.
- [15] R. J. Valderrábano and M. I. Linares, "Diabetes mellitus, bone health: epidemiology, etiology and implications for fracture risk stratification," *Clinical Diabetes and Endocrinology*, vol. 4, no. 1, Dec. 2018, doi: 10.1186/S40842-018-0060-9.
- [16] Z. Chen, G. H. Zhao, Y. K. Zhang, G. S. Shen, Y. J. Xu, and N. W. Xu, "Research on the correlation of diabetes mellitus complicated with osteoporosis with lipid metabolism, adipokines and inflammatory factors and its regression analysis," *European Journal for Medical and Pharmaceutical Sciences*, vol. 21, no. 17, pp. 3900–3905, Oct. 2017.
- [17] M. Ock, S. Lee, and H. Kim, "Osteoporosis or fracture risk associated with thiazolidinedione and proton pump inhibitor co-administration in patients with type 2 diabetes mellitus," *Journal of Clinical Pharmacy and Therapeutics*, vol. 47, no. 7, pp. 1028–1035, Jul. 2022, doi: 10.1111/JCPT.13640.
- [18] J. Charan and T. Biswas, "How to calculate sample size for different study designs in medical research?" *Indian Journal of Psychological Medicine*, vol. 35, no. 2, p. 121, Apr. 2013, doi: 10.4103/0253-7176.116232.
- [19] B. Liu, J. Liu, J. Pan, C. Zhao, Z. Wang, and Q. Zhang, "The association of diabetes status and bone mineral density among US adults: evidence from NHANES 2005–2018," *BMC Endocrine Disorders*, vol. 23, no. 1, pp. 1–9, Dec. 2023, doi: 10.1186/S12902-023-01266-W/TABLES/4.
- [20] T. Sözen, L. Özışık, and N. Ç. Başaran, "An overview and management of osteoporosis," *European Journal of Rheumatology*, vol. 4, no. 1, p. 46, Mar. 2017, doi: 10.5152/EURJRHEUM.2016.048.
- [21] G. A. Greendale, M. H. Huang, J. A. Cauley, S. Harlow, J. S. Finkelstein, and A. S. Karlamangla, "Premenopausal and early postmenopausal trabecular bone score (TBS) and fracture risk: Study of Women's Health Across the Nation (SWAN)," *Bone*, vol. 140, p. 115547, Nov. 2020, doi: 10.1016/J.BONE.2020.115543.
- [22] Y. Chen *et al.*, "Systemic inflammation markers associated with bone mineral density in perimenopausal and postmenopausal women," *Journal of Inflammation Research*, vol. 16, pp. 297–309, 2023, doi: 10.2147/JIR.S385220.
- [23] L. T. Ho-Pham, H. G. Nguyen, S. Q. Nguyen-Pham, D. K. Hoang, T. S. Tran, and T. V. Nguyen, "Longitudinal changes in bone mineral density during perimenopausal transition: the Vietnam Osteoporosis Study," *Osteoporosis International*, vol. 34, no. 8, pp. 1381–1387, Aug. 2023, doi: 10.1007/S00198-023-06757-Z.
- [24] A. S. Karlamangla, S. A. M. Burnett-Bowie, and C. J. Crandall, "Bone health during the menopause transition and beyond," *Obstetrical Gynecological Clinics of North America*, vol. 45, no. 4, pp. 695–708, Dec. 2018, doi: 10.1016/J.jogc.2018.07.012.
- [25] D. Qiao *et al.*, "Association of obesity with bone mineral density and osteoporosis in adults: a systematic review and meta-analysis," *Public Health*, vol. 12, p. 180, pp. 22–28, Mar. 2020, doi: 10.1016/J.PUHE.2019.11.001.
- [26] J. Vavanikunnel *et al.*, "Association Between Glycemic Control and Risk of Fracture in Diabetic Patients: A Nested Case-Control Study," *The Journal of Clinical Endocrinology & Metabolism*, vol. 104, no. 5, pp. 1645–1654, May 2019, doi: 10.1210/clinem.2018-01879.
- [27] A. V. Schwartz *et al.*, "Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial," *Diabetes Care*, vol. 35, no. 7, pp. 1525–1531, Jul. 2012, doi: 10.2337/DC11-2184.
- [28] K. Hidayat, Q. L. Fang, B. M. Shi, and L. Q. Qin, "Influence of glycemic control and hypoglycemia on the risk of fracture in patients with diabetes mellitus: a systematic review and meta-analysis of observational studies," *Osteoporosis International*, vol. 32, no. 9, pp. 1693–1704, Sep. 2021, doi: 10.1007/s00198-021-05934-2.
- [29] F. Poursmaeili, B. Kamalidehghan, M. Kamarehei, and Y. M. Goh, "A comprehensive overview on osteoporosis and its risk factors," *Therapeutics and Clinical Risk Management*, vol. 14, pp. 2029–2049, 2018, doi: 10.2147/TCRM.S138000.
- [30] I. Kanazawa and T. Sugimoto, "Diabetes mellitus-induced bone fragility," *Internal Medicine*, vol. 57, no. 19, pp. 2773–2785, 2018, doi: 10.2169/INTERNALMEDICINE.0905-18.
- [31] K. Hidayat, X. Du, M. J. Wu, and B. M. Shi, "The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies," *Obesity Reviews*, vol. 20, no. 10, pp. 1494–1503, Oct. 2019, doi: 10.1111/OBR.12885.
- [32] C. Kumari, G. Yagoub, M. Ashfaq, S. Jawed, and P. Hamid, "Consequences of diabetes mellitus in bone health: traditional review," *Cureus*, Mar. 2021, doi: 10.7759/CUREUS.13820.





**BIOGRAPHIES OF AUTHORS**

**Heri Nugroho**     is a lecturer at the Internal Medicine Department, Faculty of Medicine, Diponegoro University. He is active in the Division of Endocrinology, Metabolism and Diabetes. He is an active speaker in both local and international conferences on endocrine, diabetes and metabolic diseases. He can be contacted at email: [khris\\_heri@yahoo.com](mailto:khris_heri@yahoo.com).



**Rizal Kurniawan**     is a medical doctor specializing in Internal Medicine. He graduated from Faculty of Medicine, Diponegoro University. His special interest in research is diabetes, endocrine and metabolic diseases. He can be contacted at email: [dr.rizal.k@gmail.com](mailto:dr.rizal.k@gmail.com).



**Cahya Tri Purnami**     is an assistant professor at Department of Biostatistics, Faculty of Public Health, Diponegoro University. She is and active researcher and speaker in various fields of public health. She can be contacted at email: [cahyatp68@gmail.com](mailto:cahyatp68@gmail.com).



# Bone mineral density and osteoporosis related risk factors in type 2 diabetes mellitus

## ORIGINALITY REPORT

24%

SIMILARITY INDEX

21%

INTERNET SOURCES

16%

PUBLICATIONS

12%

STUDENT PAPERS

## PRIMARY SOURCES

- 1** [www.swanstudy.org](http://www.swanstudy.org) Internet Source 1%
- 2** Submitted to University of Sydney Student Paper 1%
- 3** Chao Liang, Rongxin Sun, Yifan Xu, Wei Geng, Jun Li. "Effect of the Abnormal Expression of BMP-4 in the Blood of Diabetic Patients on the Osteogenic Differentiation Potential of Alveolar BMSCs and the Rescue Effect of Metformin: A Bioinformatics-Based Study", BioMed Research International, 2020 Publication 1%
- 4** Submitted to University of Sheffield Student Paper 1%
- 5** [www.reliasmedia.com](http://www.reliasmedia.com) Internet Source 1%
- 6** Xuan Dai, Yage Liu, Tianyuan Liu, Yueyi Zhang et al. "SijunZi decoction ameliorates bone quality and redox homeostasis and regulates

advanced glycation end products/receptor for advanced glycation end products and WNT/ $\beta$ -catenin signaling pathways in diabetic mice",  
Journal of Ethnopharmacology, 2023

Publication

---

7	<a href="https://qspace.library.queensu.ca">qspace.library.queensu.ca</a> Internet Source	1 %
8	<a href="https://actamedindones.org">actamedindones.org</a> Internet Source	1 %
9	<a href="https://palm.seu.edu.cn">palm.seu.edu.cn</a> Internet Source	1 %
10	Submitted to California State University, Sacramento Student Paper	1 %
11	Submitted to Loughborough College Student Paper	1 %
12	Submitted to University Of Tasmania Student Paper	1 %
13	<a href="https://rsdjournal.org">rsdjournal.org</a> Internet Source	1 %
14	<a href="https://researchers.uq.edu.au">researchers.uq.edu.au</a> Internet Source	1 %
15	<a href="https://scholarworks.sjsu.edu">scholarworks.sjsu.edu</a> Internet Source	1 %
16	<a href="https://bmc.altmetric.com">bmc.altmetric.com</a> Internet Source	

---

<1 %

17

[cris.technion.ac.il](http://cris.technion.ac.il)

Internet Source

<1 %

18

[e-century.us](http://e-century.us)

Internet Source

<1 %

19

Submitted to Canterbury Christ Church  
University

Student Paper

<1 %

20

[ijaas.iaescore.com](http://ijaas.iaescore.com)

Internet Source

<1 %

21

[prism.ucalgary.ca](http://prism.ucalgary.ca)

Internet Source

<1 %

22

Submitted to Universitas Riau

Student Paper

<1 %

23

Submitted to University of Birmingham

Student Paper

<1 %

24

[narraj.org](http://narraj.org)

Internet Source

<1 %

25

[pubmed.ncbi.nlm.nih.gov](http://pubmed.ncbi.nlm.nih.gov)

Internet Source

<1 %

26

Submitted to Christchurch Polytechnic  
Institute of Technology

Student Paper

<1 %

27	<a href="https://dovemedicalpress.altmetric.com">dovemedicalpress.altmetric.com</a> Internet Source	<1 %
28	<a href="https://www.scribd.com">www.scribd.com</a> Internet Source	<1 %
29	<a href="https://ijai.iaescore.com">ijai.iaescore.com</a> Internet Source	<1 %
30	"Mini Orals", Nephrology, 2018 Publication	<1 %
31	Submitted to Tung Wah College Student Paper	<1 %
32	<a href="https://link.springer.com">link.springer.com</a> Internet Source	<1 %
33	"ALLIED HEALTH PROFESSIONALS", APLAR Journal of Rheumatology, 8/2006 Publication	<1 %
34	<a href="https://bmccardiovascdisord.biomedcentral.com">bmccardiovascdisord.biomedcentral.com</a> Internet Source	<1 %
35	Samican Ozmen, Sefa Kurt, Hikmet Tunc Timur, Onur Yavuz, Ali Hakan Kula, Ayşegül Yılmaz Demir, Ali Balci. "Prevalence and Risk Factors of Osteoporosis: a Cross-Sectional Study in a Tertiary Center", Research Square Platform LLC, 2024 Publication	<1 %
36	<a href="https://he02.tci-thaijo.org">he02.tci-thaijo.org</a> Internet Source	



<1 %

37

[www-emerald-com-443.webvpn.sxu.edu.cn](http://www-emerald-com-443.webvpn.sxu.edu.cn)

Internet Source

<1 %

38

Peiyang Song, Tianyi Chen, Shunli Rui, Xiaodong Duan, Bo Deng, David G. Armstrong, Yu Ma, Wuquan Deng. "Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice", *Frontiers in Endocrinology*, 2022

Publication

<1 %

39

[ijece.iaescore.com](http://ijece.iaescore.com)

Internet Source

<1 %

40

[dmsjournal.biomedcentral.com](http://dmsjournal.biomedcentral.com)

Internet Source

<1 %

41

[pure.tue.nl](http://pure.tue.nl)

Internet Source

<1 %

42

[www.liebertpub.com](http://www.liebertpub.com)

Internet Source

<1 %

43

Haripriya Kuchi Bhotla, Arun Meyyazhagan, Karthika Pushparaj, Manikantan Pappuswamy et al. "Prevalence of cardiovascular diseases in South Asians: Scrutinizing traditional risk factors and newly recognized risk factors

<1 %

sarcopenia and osteopenia/osteoporosis",  
Current Problems in Cardiology, 2023

Publication

44

Qoni Mulia Sagita, Yuliani Setyaningsih,  
Sulistiyani Sulistiyani. "Determinant Factors of  
Work-Related Complaints", International  
Journal of Public Health Science (IJPHS), 2018

Publication

<1 %

45

William B. Roepke, Amgad M. Haleem.  
"Complications of Foot and Ankle Fractures in  
Diabetics", Foot and Ankle Clinics, 2024

Publication

<1 %

46

Z. Yang, J. Liu, J. Fu, S. Li, Z. Chai, Y. Sun.  
"Associations between WNT signaling  
pathway-related gene polymorphisms and  
risks of osteoporosis development in Chinese  
postmenopausal women: a case-control  
study", Climacteric, 2021

Publication

<1 %

47

[discovery.dundee.ac.uk](http://discovery.dundee.ac.uk)

Internet Source

<1 %

48

[docksci.com](http://docksci.com)

Internet Source

<1 %

49

[www.bjorl.org](http://www.bjorl.org)

Internet Source

<1 %

50

[www.preprints.org](http://www.preprints.org)

Internet Source

<1 %

51	<a href="http://www.science.gov">www.science.gov</a> Internet Source	<1 %
52	<a href="http://dergipark.org.tr">dergipark.org.tr</a> Internet Source	<1 %
53	<a href="http://e-journal.trisakti.ac.id">e-journal.trisakti.ac.id</a> Internet Source	<1 %
54	<a href="http://mdanderson.influent.utsystem.edu">mdanderson.influent.utsystem.edu</a> Internet Source	<1 %
55	<a href="http://sciencerepository.org">sciencerepository.org</a> Internet Source	<1 %
56	Carrie M Nielson, Lynn M Marshall, Annette L Adams, Erin S LeBlanc et al. "BMI and fracture risk in older men: The osteoporotic fractures in men study (MrOS)", Journal of Bone and Mineral Research, 2011 Publication	<1 %
57	Submitted to Mansoura University Student Paper	<1 %
58	<a href="http://archpublichealth.biomedcentral.com">archpublichealth.biomedcentral.com</a> Internet Source	<1 %
59	<a href="http://bmccancer.biomedcentral.com">bmccancer.biomedcentral.com</a> Internet Source	<1 %
60	<a href="http://clinicalsocialwork.eu">clinicalsocialwork.eu</a> Internet Source	<1 %

61

Internet Source

<1 %

62

[qspace.qu.edu.qa](https://qspace.qu.edu.qa)

Internet Source

<1 %

63

[www.x-mol.com](http://www.x-mol.com)

Internet Source

<1 %

64

"Issue Information", Journal of Clinical Pharmacy and Therapeutics, 2022

Publication

<1 %

65

"Poster Presentations", Journal of Gastroenterology and Hepatology, 2023

Publication

<1 %

66

Alexander Eckert, Julia K. Mader, Marcus Altmeier, Steffen Mühldorfer et al. "Fracture risk in patients with type 2 diabetes aged ≥50years related to HbA1c, acute complications, BMI and SGLT2i-use in the DPV registry", Journal of Diabetes and its Complications, 2020

Publication

<1 %

67

Pijun Yan, Yuxia Yang, Xing Zhang, Yi Zhang et al. "Association of systemic immune-inflammation index with diabetic kidney disease in patients with type 2 diabetes: a cross-sectional study in Chinese population", Frontiers in Endocrinology, 2024

Publication

<1 %



68

Vicente F C Andrade, Débora Besen, Domingos C Chula, Victória Z C Borba, David Dempster, Carolina Aguiar Moreira. "Bone marrow adiposity in premenopausal women with type 2 diabetes with observations on peri-trabecular adipocytes", The Journal of Clinical Endocrinology & Metabolism, 2021

Publication

<1 %

69

Clara Sanz-Nogués, Mohamad Mustafa, Helen Burke, Timothy O'Brien, Cynthia M. Coleman. "Knowledge, Perceptions and Concerns of Diabetes-Associated Complications among Individuals Living with Type 1 and Type 2 Diabetes Mellitus", Healthcare, 2020

Publication

<1 %

Exclude quotes Off

Exclude matches Off

Exclude bibliography Off